본문 바로가기
KERD
논문KCI 등재

Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

초록

Background/Aims: There is increasing evidence that supplementation with pre- and probiotics appears to have positive effects on irritable bowel syndrome (IBS). The aim of this study was to determine the effects of a new synbiotic formulation on gastrointestinal symptoms in elderly patients with IBS. Methods: Sixty-seven IBS patients aged ≥60 years were randomly assigned to either a placebo group (n=34) or a synbiotic group (n=33). During a 4-week intervention, subjects used a placebo or a synbiotic containing Lactobacillus paracasei DKGF1 and extracts of Opuntia humifusa once a day. Patients were evaluated with the subject global assessment, visual analog scale, and Bristol stool chart. The primary outcome was the overall responder rate and the secondary outcome was the responder rates for abdominal symptom reduction at week 4. Results: Overall, responder rates were significantly higher in the synbiotic group (51.5%) than in the placebo group (23.5%) (p=0.017). Abdominal pain (58.8% vs 81.8%) and psychological well-being (26.4% vs 60.6%) were noticeably improved in the synbiotic group (p=0.038 and p=0.004, respectively). However, there were no significant differences in gas and bloating symptoms (p=0.88 and p=0.88, respectively). In patients with constipation-dominant and diarrhea-dominant IBS (n=16), the synbiotic significantly improved abdominal pain and defecation symptoms (responder rates for the placebo vs the synbiotic: 22.2% vs 85.7%, p=0.04). There were no adverse events in either group. Conclusions: The results indicate that this new synbiotic supplement can potentially relieve abdominal symptoms in elderly IBS patients.

Abstract

Background/Aims: There is increasing evidence that supplementation with pre- and probiotics appears to have positive effects on irritable bowel syndrome (IBS). The aim of this study was to determine the effects of a new synbiotic formulation on gastrointestinal symptoms in elderly patients with IBS. Methods: Sixty-seven IBS patients aged ≥60 years were randomly assigned to either a placebo group (n=34) or a synbiotic group (n=33). During a 4-week intervention, subjects used a placebo or a synbiotic containing Lactobacillus paracasei DKGF1 and extracts of Opuntia humifusa once a day. Patients were evaluated with the subject global assessment, visual analog scale, and Bristol stool chart. The primary outcome was the overall responder rate and the secondary outcome was the responder rates for abdominal symptom reduction at week 4. Results: Overall, responder rates were significantly higher in the synbiotic group (51.5%) than in the placebo group (23.5%) (p=0.017). Abdominal pain (58.8% vs 81.8%) and psychological well-being (26.4% vs 60.6%) were noticeably improved in the synbiotic group (p=0.038 and p=0.004, respectively). However, there were no significant differences in gas and bloating symptoms (p=0.88 and p=0.88, respectively). In patients with constipation-dominant and diarrhea-dominant IBS (n=16), the synbiotic significantly improved abdominal pain and defecation symptoms (responder rates for the placebo vs the synbiotic: 22.2% vs 85.7%, p=0.04). There were no adverse events in either group. Conclusions: The results indicate that this new synbiotic supplement can potentially relieve abdominal symptoms in elderly IBS patients.

참고문헌 (42)

  1. Chey WD, "Irritable bowel syndrome : a clinical review", JAMA, 313, pp.949~958 (2015)
  2. Black CJ, "Global burden of irritable bowel syndrome : trends, predictions and risk factors", Nat Rev Gastroenterol Hepatol, 17, pp.473~486 (2020)
  3. Wang Y, "A genetic association study of single nucleotide polymorphisms in GNβ3 and COMT in elderly patients with irritable bowel syndrome", Med Sci Monit, 20, pp.1246~1254 (2014)
  4. Bharucha AE, "Functional abdominal pain in the elderly", Gastroenterol Clin North Am, 30, pp.517~529 (2001)
  5. Kurniawan I, "Management of irritable bowel syndrome in the elderly", Acta Med Indones, 46, pp.138~147 (2014)
  6. Ford AC, "Irritable bowel syndrome", N Engl J Med, 376, pp.2566~2578 (2017)
  7. Malinen E, "Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR", Am J Gastroenterol, 100, pp.373~382 (2005)
  8. Si JM, "Intestinal microecology and quality of life in irritable bowel syndrome patients", World J Gastroenterol, 10, pp.1802~1805 (2004)
  9. Parkes GC, "Treating irritable bowel syndrome with probiotics : the evidence", Proc Nutr Soc, 69, pp.187~194 (2010)
  10. Hill C, "Expert consensus document : the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic", Nat Rev Gastroenterol Hepatol, 11, pp.506~514 (2014)
  11. Guarner F, "World Gastroenterology Organisation Global Guidelines : probiotics and prebiotics October 2011", J Clin Gastroenterol, 46, pp.468~481 (2012)
  12. Ford AC, "Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation : systematic review and metaanalysis", Am J Gastroenterol, 109, pp.1547~1561 (2014)
  13. Spiller R, "Review article : probiotics and prebiotics in irritable bowel syndrome", Aliment Pharmacol Ther, 28, pp.385~396 (2008)
  14. Oh JH, "Efficacy and safety of new Lactobacilli probiotics for unconstipated irritable bowel syndrome : a randomized, double-blind, placebocontrolled trial", Nutrients, 11, pp.2887~ (2019)
  15. Lewis ED, "Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in alleviating symptoms of irritable bowel syndrome(IBS) : a randomized, placebo-controlled study", Nutrients, 12, pp.1159~ (2020)
  16. Andriulli A, "Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study", J Clin Gastroenterol, 42(Suppl 3 Pt 2), pp.S218~S223 (2008)
  17. Juan Carlos Guevara-Arauza, "Prebiotic Effect of Mucilage and Pectic-derived Oligosaccharides from Nopal (Opuntia ficus-indica)", Food Science and Biotechnology, 21(4), pp.997~1003 (2012), 한국식품과학회[DOI]
  18. Avila-Nava A, "Extract of cactus(Opuntia ficus indica)cladodes scavenges reactive oxygen species in vitro and enhances plasma antioxidant capacity in humans", J Funct Foods, 10, pp.13~24 (2014)
  19. Gullón B, "In vitro assessment of the prebiotic potential of Aloe vera mucilage and its impact on the human microbiota", Food Funct, 6, pp.525~531 (2015)
  20. Chung WS, "Prebiotic potential of pectin and pectic oligosaccharides to promote anti-inflammatory commensal bacteria in the human colon", FEMS Microbiol Ecol, 93, pp.fix127~ (2017)
  21. Seong G, "Effect of a synbiotic containing Lactobacillus paracasei and Opuntia humifusa on a murine model of irritable bowel syndrome", Nutrients, 12, pp.3205~ (2020)
  22. Drossman DA, "Rome IV-functional GI disorders : disorders of gut-brain interaction", Gastroenterology, 150, pp.1257~1261 (2016)
  23. Bengtsson M, "Development and psychometric testing of the visual analogue scale for irritable bowel syndrome(VAS-IBS)", BMC Gastroenterol, 7, pp.16~ (2007)
  24. Blake MR, "Validity and reliability of the Bristol stool form scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome", Aliment Pharmacol Ther, 44, pp.693~703 (2016)
  25. Müller-Lissner S, "Subject’s global assessment of relief : an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials", J Clin Epidemiol, 56, pp.310~316 (2003)
  26. Hong Yeol Yoo, "Validation of the Korean version of visual analogue scale for irritable bowel syndrome questionnaire for assessment of defecation pattern changes", Annals of Surgical Treatment and Research, 94(5), pp.254~261 (2018), 대한외과학회
  27. Tsuchiya J, "Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome", Chin J Dig Dis, 5, pp.169~174 (2004)
  28. Shavakhi A, "The effects of multi-strain probiotic compound on symptoms and qualityof-life in patients with irritable bowel syndrome : a randomized placebo-controlled trial", Adv Biomed Res, 3, pp.140~ (2014)
  29. Ford AC, "Systematic review with meta-analysis : the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome", Aliment Pharmacol Ther, 48, pp.1044~1060 (2018)
  30. Power SE, "Intestinal microbiota, diet and health", Br J Nutr, 111, pp.387~402 (2014)
  31. Saraswati S, "Aging and the human gut microbiota-from correlation to causality", Front Microbiol, 5, pp.764~ (2015)
  32. O’Toole PW, "Gut microbiota and aging", Science, 350, pp.1214~1215 (2015)
  33. Damodharan K, "Probiotic characterization of Lactobacillus paracasei subsp. paracasei KNI9 inhibiting adherence of Yersinia enterocolitica on Caco-2 cells in vitro", Probiotics Antimicrob Proteins, 12, pp.600~607 (2020)
  34. Cremon C, "Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome : a pilot randomized clinical trial", United European Gastroenterol J, 6, pp.604~613 (2018)
  35. Markowiak P, "Effects of probiotics, prebiotics, and synbiotics on human health", Nutrients, 9, pp.1021~ (2017)
  36. Holscher HD, "Dietary fiber and prebiotics and the gastrointestinal microbiota", Gut Microbes, 8, pp.172~184 (2017)
  37. Cho JY, "Radical scavenging and anti-inflammatory activity of extracts from Opuntia humifusa Raf", J Pharm Pharmacol, 58, pp.113~119 (2006)
  38. Larsen N, "The effect of pectins on survival of probiotic Lactobacillus spp. in gastrointestinal juices is related to their structure and physical properties", Food Microbiol, 74, pp.11~20 (2018)
  39. Han SH, "Cactus(Opuntia humifusa)water extract ameliorates loperamideinduced constipation in rats", BMC Complement Altern Med, 17, pp.49~ (2017)
  40. Qumseya BJ, "Irritable bowel syndrome in middle-aged and elderly Palestinians : its prevalence and effect of location of residence", Am J Gastroenterol, 109, pp.723~739 (2014)
  41. Lackner J, "Patient-reported outcomes for irritable bowel syndrome are associated with patients’severity ratings of gastrointestinal symptoms and psychological factors", Clin Gastroenterol Hepatol, 9, pp.957~964 (2011)
  42. Enck P, "Irritable bowel syndrome", Nat Rev Dis Primers, 2, pp.16014~ (2016)

관련 논문AI추천

Comments on Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled TrialKim Kwang Woo거트앤리버 소화기연관학회협의회 · Gut and Liver2023 · 제17권 제6호A Randomized Clinical Trial of Synbiotics in Irritable Bowel Syndrome: Dose-Dependent Effects on Gastrointestinal Symptoms and Fatigue김규남, Doo-Yeoun Cho, Jin-Ho Kim, Kyung-Sun Han, Sang-Hoon Lee, Seok-Hoon Lee, Soo-Min Kim, Su-Hyun Lee, Sung-Won Yang대한가정의학회 · Korean Journal of Family Medicine2019 · 제40권 제1호Effect of Probiotics on Symptoms in Korean Adults with Irritable Bowel Syndrome김상균, 김주성, 송인성, 임종필, 정현채, 지근억, 홍경섭, Hyoun Woo Kang거트앤리버 소화기연관학회협의회 · Gut and Liver2009 · 제3권 제2호Probiotic Fermented Milk Containing Dietary Fiber Has Additive Effects in IBS with Constipation Compared to Plain Probiotic Fermented Milk김범진, 심기현, 장동경, Hee Jung Son, Jae J. Kim, Jong Chul Rhee, Poong-Lyul Rhee, Seok Nam Park, Soon Im Kim, Sung Chul Choi, Young Sil Han거트앤리버 소화기연관학회협의회 · Gut and Liver2011 · 제5권 제1호Pharmacologic and Complementary and Alternative Medicine Therapies for Irritable Bowel SyndromeMonthira Maneerattaporn, Richard Saad, William D. Chey거트앤리버 소화기연관학회협의회 · Gut and Liver2011 · 제5권 제3호Impact of Probiotic Formula (Lacto-5X) on Constipation: Improvements in Gastrointestinal Symptoms, Gut Microbiome, and MetabolitesChoi Jieun, Jin Yoo-Jeong, Kang Jooyeon, Kim Byung-Yong, Kim Myung-Soo, Lee Do Yup, Lim Jong Hyun, Min Uigi, Park Young Jae한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2025 · 제35권

이 간행물의 다른 논문 (20건)